Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: Results of multicenter cohort study and review of the literature

Autoimmunity Reviews

Volumn 11, Issue 1, 2011, Pages 48-55

  Ferri, C ^a   Cacoub, P ^b   Mazzaro, C ^c   Roccatello, D ^d   Scaini, P ^e   Sebastiani, M ^a   Tavoni, A ^f   Zignego, A L ^g   De Vita, S ^h  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c Pordenone General Hospital   (Italy)

^d S GIOVANNI BOSCO HOSPITAL   (Italy)

^e SPEDALI CIVILI   (Italy)

^f UNIVERSITY OF PISA   (Italy)

^g UNIVERSITY OF FLORENCE   (Italy)

^h SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

Author keywords

Anti CD20; Cryoglobulinemic vasculitis; Hepatitis C virus; Mixed cryoglobulinemia; Rituximab

Indexed keywords

COMPLEMENT COMPONENT C4; CREATININE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; PEGINTERFERON ALPHA; PREDNISONE; RIBAVIRIN; RITUXIMAB; VINCRISTINE;

ADULT; B CELL LYMPHOMA; COHORT ANALYSIS; CREATININE BLOOD LEVEL; CRYOGLOBULINEMIA; CRYOGLOBULINEMIC NEPHROPATHY; DISEASE DURATION; DRUG EFFECT; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; INFECTION; INFUSION RELATED REACTION; KIDNEY DISEASE; LEG ULCER; MAJOR CLINICAL STUDY; MALE; MEDICAL LITERATURE; MEDLINE; MIXED CRYOGLOBULINEMIA SYNDROME; PARESTHESIA; PERIPHERAL NEUROPATHY; PLASMAPHERESIS; PROTEINURIA; PRURITUS; REMISSION; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VASCULITIS; VISUAL ANALOG SCALE;

AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; COHORT STUDIES; CRYOGLOBULINEMIA; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; MALE; MIDDLE AGED; SYNDROME; TREATMENT OUTCOME;

EID: 80855123812     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2011.07.005     Document Type: Review

References (63)

1. Gorevic P.D., Kassab H.J., Levo Y., Kohn R., Meltzer M., Prose P., et al. Mixed cryoglobulinemia: clinical aspects and long-term follow-up of 40 patients. Am J Med 1980, 69:287-308.
2. Brouet J.C., Clauvel J.P., Danon F., Klein M., Seligmann M. Biologic and clinical significance of cryoglobulins. A report of 86 cases. Am J Med 1974, 57:775-788.
3. Ferri C., Zignego A.L., Pileri S.A. Cryoglobulins. J Clin Pathol 2002, 55:4-13.
4. Ferri C., Monti M., La Civita L., Longombardo G., Greco F., Pasero G., et al. Infection of peripheral blood mononuclear cells by hepatitis C virus in mixed cryoglobulinemia. Blood 1993, 82:3701-3704.
5. Ferri C., Sebastiani M., Giuggioli D., Cazzato M., Longombardo G., Antonelli A., et al. Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients. Semin Arthritis Rheum 2004, 33:355-374.
6. Pietrogrande M., De Vita S., Zignego A.L., Pioltelli P., Sansonno D., Sollima S., et al. Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients. Autoimmun Rev 2011, 10:444-454.
7. Saadoun D., Resche-Rigon M., Thibault V., Piette J.C., Cacoub P. Antiviral therapy for hepatitis C virus-associated mixed cryoglobulinemia vasculitis: a long-term followup study. Arthritis Rheum 2006, 54:3696-3706.
8. Mazzaro C., Pozzato G., Zorat F., Baragiotta A.M., Biscontin M.G., Spina M., et al. Etiologic treatment of hepatitis C virus-associated mixed cryoglobulinemia. Dig Liver Dis 2007, 39:S102-S106.
9. Zaja F., Russo D., Fuga G., Patriarca F., Ermacora A., Baccarani M. Rituximab for the treatment of type II mixed cryoglobulinemia. Haematologica 1999, 84:1157-1158.
10. Arzoo K., Sadeghi S., Liebman H.A. Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab). Ann Rheum Dis 2002, 61:922-924.
11. Zaja F., De Vita S., Russo D., Michelutti A., Fanin R., Ferraccioli G., et al. Rituximab for the treatment of type II mixed cryoglobulinemia. Arthritis Rheum 2002, 46:2252-2254.
12. Sansonno D., De Re V., Lauletta G., Tucci F.A., Boiocchi M., Dammacco F. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood 2003, 101:3818-3826.
13. Engel P., Gómez-Puerta J.A., Ramos-Casals M., Lozano F., Bosch X. Therapeutic targeting of B cells for rheumatic autoimmune diseases. Pharmacol Rev 2011, 63:127-156.
14. Wang C., Pan H.F., Ye D.Q. The therapeutic potential of the targeted autoreactive B lymphocytes by rituximab in SLE. Autoimmun Rev 2011, [Epub ahead of print].
15. Bosello S., De Luca G., Tolusso B., Lama G., Angelucci C., Sica G., et al. B cells in systemic sclerosis: a possible target for therapy. Autoimmun Rev 2011, [Epub ahead of print].
16. Perosa F., Prete M., Racanelli V., Dammacco F. CD20-depleting therapy in autoimmune diseases: from basic research to the clinic. J Intern Med 2010, 167:260-277.
17. Scoble T., Wijetilleka S., Khamashta M.A. Management of refractory anti-phospholipid syndrome. Autoimmun Rev 2011, [Epub ahead of print].
18. Marie I., Mouthon L. Therapy of polymyositis and dermatomyositis. Autoimmun Rev 2011, [Epub ahead of print].
19. Kieseier B.C., Lehmann H.C., Horste G.M. Autoimmune diseases of the peripheral nervous system. Autoimmun Rev 2011, [Epub ahead of print].
20. Rutgers A., Kallenberg C.G. Refractory vasculitis. Autoimmun Rev 2011, [Epub ahead of print].
21. Fabris M., Quartuccio L., Lombardi S., Saracco M., Atzeni F., Carletto A., et al. The CC homozygosis of the -174G>C IL-6 polymorphism predicts a lower efficacy of rituximab therapy in rheumatoid arthritis. Autoimmun Rev 2010, [Epub ahead of print].
22. Galarza-Maldonado C., Kourilovitch M.R., Molineros J.E., Cardiel M.H., Zurita L., Soroka N.F., et al. The administration of low doses of rituximab followed by hydroxychloroquine, prednisone and low doses of mycophenolate mofetil is an effective therapy in Latin American patients with active systemic lupus erythematosus. Autoimmun Rev 2010, 10:108-111.
23. Conti F., Perricone C., Ceccarelli F., Valesini G. Rituximab treatment of systemic lupus erythematosus in controlled trials and in clinical practice: two sides of the same coin. Autoimmun Rev 2010, 9:716-720.
24. De Vita S., Quartuccio L., Fabris M. Rituximab in mixed cryoglobulinemia: increased experience and perspectives. Dig Liver Dis 2007, 39:S122-S128.
25. Roccatello D., Baldovino S., Rossi D., Giachino O., Mansouri M., Naretto C., et al. Rituximab as a therapeutic tool in severe mixed cryoglobulinemia. Clin Rev Allergy Immunol 2008, 34:111-117.
26. Saadoun D., Resche-Rigon M., Sene D., Perard L., Karras A., Cacoub P. Rituximab combined with Peg-interferon-ribavirin in refractory hepatitis C virus-associated cryoglobulinaemia vasculitis. Ann Rheum Dis 2008, 67:1431-1436.
27. Cavallo R., Roccatello D., Menegatti E., Naretto C., Napoli F., Baldovino S. Rituximab in cryoglobulinemic peripheral neuropathy. J Neurol 2009, 256:1076-1082.
28. Petrarca A., Rigacci L., Caini P., Colagrande S., Romagnoli P., Vizzutti F., et al. Safety and efficacy of rituximab in patients with hepatitis C virus related mixed cryoglobulinemia and severe liver disease. Blood 2010, 116:335-342.
29. Saadoun D., Resche Rigon M., Sene D., Terrier B., Karras A., Perard L., et al. Rituximab plus Peg-interferon-alpha/ribavirin compared with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia. Blood 2010, 116:326-334.
30. Dammacco F., Tucci F.A., Lauletta G., Gatti P., De Re V., Conteduca V., et al. Pegylated interferon-alpha, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study. Blood 2010, 116:343-353.
31. Visentini M., Ludovisi S., Petrarca A., Pulvirenti F., Zaramella M., Monti M., et al. A phase II, single-arm multicenter study of low-dose rituximab for refractory mixed cryoglobulinemia secondary to hepatitis C virus infection. Autoimmun Rev 2011, 10.1016/j.autrev.2011.04.033.
32. De Vita S., Soldano F., Isola M., Monti G., Gabrielli A., Tzioufas A., et al. Preliminary classification criteria for the cryoglobulinaemic vasculitis. Ann Rheum Dis 2011, 70:1183-1190.
33. Ferri C. Mixed cryoglobulinemia. Orphanet J Rare Dis 2008, 3:25.
34. Terrier B., Launay D., Kaplanski G., Hot A., Larroche C., Cathébras P., et al. Safety and efficacy of rituximab in non-viral cryoglobulinemia vasculitis: data from the French AIR registry. Arthritis Care Res 2010, 62:1787-1795.
35. Zaja F., De Vita S., Mazzaro C., Sacco S., Damiani D., De Marchi G., et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 2003, 101:3827-3834.
36. Lamprecht P., Lerin-Lozano C., Merz H., Dennin R.H., Gause A., Voswinkel J., et al. Rituximab induces remission in refractory HCV associated cryoglobulinaemic vasculitis. Ann Rheum Dis 2003, 62:1230-1233.
37. Roccatello D., Baldovino S., Rossi D., Mansouri M., Naretto C., Gennaro M., et al. Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis. Nephrol Dial Transplant 2004, 19:3054-3061.
38. Ghobrial I.M., Uslan D.Z., Call T.G., Witzig T.E., Gertz M.A. Initial increase in the cryoglobulin level after rituximab therapy for type II cryoglobulinemia secondary to Waldenstrom macroglobulinemia does not indicate failure of response. Am J Hematol 2004, 77:329-330.
39. Ghijsels E., Lerut E., Vanrenterghem Y., Kuypers D. Anti-CD20 monoclonal antibody (rituximab) treatment for hepatitis C-negative therapy-resistant essential mixed cryoglobulinemia with renal and cardiac failure. Am J Kidney Dis 2004, 43:e34-e38.
40. Catuogno M., Rezai S., Priori R., Magrini L., Valesini G. Serum sickness associated with rituximab in a patient with hepatitis C virus-related mixed cryoglobulinaemia. Rheumatology (Oxford) 2005, 44:406.
41. Basse G., Ribes D., Kamar N., Mehrenberger M., Esposito L., Guitard J., et al. Rituximab therapy for de novo mixed cryoglobulinemia in renal transplant patients. Transplantation 2005, 80:1560-1564.
42. Koukoulaki M., Abeygunasekara S.C., Smith K.G., Jayne D.R. Remission of refractory hepatitis C-negative cryoglobulinaemic vasculitis after rituximab and infliximab. Nephrol Dial Transplant 2005, 20:213-216.
43. Quartuccio L., Soardo G., Romano G., Zaja F., Scott C.A., De Marchi G., et al. Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids. Rheumatology (Oxford) 2006, 45:842-846.
44. Cai F.Z., Ahern M., Smith M. Treatment of cryoglobulinemia associated peripheral neuropathy with rituximab. J Rheumatol 2006, 33:1197-1198.
45. Cohen H., Green S., Jones S., Amos N., William B.D. Lack of efficacy of Rituximab in a patient with essential mixed cryoglobulinaemia. Rheumatology 2007, 46:366-367.
46. Braun A., Neumann T., Oelzner P., Hein G., Gröne H.J., Ziemer M., et al. Cryoglobulinaemia type III with severe neuropathy and immune complex glomerulonephritis: remission after plasmapheresis and rituximab. Rheumatol Int 2008, 28:503-506.
47. Rego T.C., Massumoto C.M., Batista R.S., Moura L.H., Soares L.M., Gomes A.P. The use of monoclonal antibody (rituximab) in the treatment of type II mixed cryoglobulinemia. Braz J Infect Dis 2007, 11:174-175.
48. Visentini M., Granata M., Veneziano M.L., Borghese F., Carlesimo M., Pimpinelli F., et al. Efficacy of low-dose rituximab for mixed cryoglobulinemia. Clin Immunol 2007, 125:30-33.
49. Petrarca A., Rigacci L., Monti M., Giannini C., Bernardi F., Caini P., et al. Improvement in liver cirrhosis after treatment of HCV-related mixed cryoglobulinemia with rituximab. Dig Liver Dis 2007, 39:S129-S133.
50. Massari M., Catania A., Magnani G. Efficacy and risk of rituximab in type II mixed cryoglobulinemia: a significant case report. Dig Liver Dis 2007, 39:S134-S135.
51. Korte M.R., van Heerde M.J., de Man R.A., Betjes M.H. Rituximab for the treatment of glomerulonephritis in hepatitis C associated cryoglobulinaemia. Neth J Med 2008, 66:27-30.
52. da Silva Fucuta Pereira P., Lemos L.B., de Oliveira Uehara S.N., de Souza E., Silva I.S., Silva A.E., Ferraz M.L. Long-term efficacy of rituximab in hepatitis C virus-associated cryoglobulinemia. Rheumatol Int 2009, 30:1515-1518.
53. Pasa S., Altintas A., Cil T., Danis R., Ayyildiz O., Muftuoglu E. A case of essential mixed cryoglobulinemia and associated acquired von-Willebrand disease treated with rituximab. J Thromb Thrombolysis 2009, 27:220-222.
54. Tallarita T., Gagliano M., Corona D., Giuffrida G., Giaquinta A., Zerbo D., et al. Successful combination of Rituximab and plasma exchange in the treatment of cryoglobulinemic vasculitis with skin ulcers: a case report. Cases J. 2009, 2:7859.
55. Ruch J., McMahon B., Ramsey G., Kwaan H.C. Catastrophic multiple organ ischemia due to an anti-Pr cold agglutinin developing in a patient with mixed cryoglobulinemia after treatment with rituximab. Am J Hematol 2009, 84:120-122.
56. Quartuccio L., Petrarca A., Mansutti E., Pieroni S., Calcabrini L., Avellini C., et al. Efficacy of rituximab in severe and mild abdominal vasculitis in the course of mixed cryoglobulinemia. Clin Exp Rheumatol 2010, 28:s84-s87.
57. Baerlecken N.T., Schmidt R.E. Essential mixed cryoglobulinemia type III with leukocytoclastic vasculitis: remission by rituximab. Clin Rheumatol 2010, 10.1007/s10067-010-1412-8.
58. Cabibbo S., Antolino A., Garozzo G., Manenti G.O., Bonomo P. Clinical improvement induced by rituximab in two cases of type II mixed cryoglobulinaemia syndrome unresponsive to conventional treatments. Blood Transfus 2010, 8:196-198.
59. Uppal R., Charles E., Lake-Bakaar G. Acute wrist and foot drop associated with hepatitis C virus related mixed cryoglobulinemia: rapid response to treatment with rituximab. J Clin Virol 2010, 47:69-71.
60. Wink F., Houtman P.M., Jansen T.L. Rituximab in cryoglobulinaemic vasculitis, evidence for its effectivity: a case report and review of literature. Clin Rheumatol 2011, 30:293-300.
61. De Vita S., Quartuccio L., Isola M., Masolini P., Sacco S., De Marchi G., et al. A randomized, controlled, multicenter phase III study of the efficacy and safety of rituximab (RTX) monotherapy versus the best available treatment in patients with mixed cryoglobulinemia syndrome. Arthritis Rheum 2011, 62:S924.
62. Sène D., Ghillani-Dalbin P., Amoura Z., Musset L., Cacoub P. Rituximab may form a complex with IgMkappa mixed cryoglobulin and induce severe systemic reactions in patients with hepatitis C virus-induced vasculitis. Arthritis Rheum 2009, 60:3848-3855.
63. Zignego A.L., Ferri C., Pileri S.A., Caini P., Bianchi F.B. Extrahepatic manifestations of Hepatitis C Virus infection: a general overview and guidelines for a clinical approach. Dig Liver Dis 2007, 39:2-17.